Publications
Kadoch C, Treseler P, Rubenstein JL. Molecular pathogenesis of primary central nervous system lymphoma. Neurosurgical focus. 2006. PMID: 17134111
Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, Grigoriadis A, Sarrio D, Savage K, Dexter T, Iravani M, Fenwick K, Weber B, Hardisson D, Schmitt FC, Palacios J, Lakhani SR, Ashworth A. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006. PMID: 17121884
James L. Rubenstein, Cigall Kadoch, Jon Karch, Andrew Josephson, Samar Issa, Chris Becker, Howard Schulman, Lloyd Damon, Marc A. Shuman, Sushmita Roy. Identification of CSF Biomarkers for the Diagnosis of CNS Lymphoma. Blood. 2006. PMID:
Montie JE, Abrahams NA, Bahnson RR, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG, National Comprehensive Cancer Network. Bladder cancer. Clinical guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2006. PMID: 17112448
Colaco SM, Chou CL, Hauer KE. Near-peer teaching in a formative clinical skills examination. Medical education. 2006. PMID: 17054629
Hur J, Bell DW, Dean KL, Coser KR, Hilario PC, Okimoto RA, Tobey EM, Smith SL, Isselbacher KJ, Shioda T. Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein. Cancer research. 2006. PMID: 17047080
Yamashita Y, Krauze MT, Kawaguchi T, Noble CO, Drummond DC, Park JW, Bankiewicz KS. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro-oncology. 2006. PMID: 17018695
Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon L, Lopez-Plaza I, Rouault C, Crookston KP, Benjamin RJ, George J, Lin JS, Corash L, Conlan MG. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion. 2006. PMID: 17002625
Sledge GW, Rugo HS, Burstein HJ. The role of angiogenesis inhibition in the treatment of breast cancer. Clinical advances in hematology & oncology : H&O. 2006. PMID: 17139244
Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU international. 2006. PMID: 16796694
Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU international. 2006. PMID: 16796694
Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU international. 2006. PMID: 16796694
Stadler WM, Halabi S, Rini B, Ernstoff MS, Davila E, Picus J, Barrier R, Small EJ, Cancer and Leukemia Group B. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer. 2006. PMID: 16909426
Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M, Clendeninn N, Mani S. Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma. Investigational new drugs. 2006. PMID: 16957834
Bartlett DL, Berlin J, Lauwers GY, Messersmith WA, Petrelli NJ, Venook AP. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Annals of surgical oncology. 2006. PMID: 16955384
Lin AM, Hershberg RM, Small EJ. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urologic oncology. 2006. PMID: 16962496
Lin AM, Hershberg RM, Small EJ. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urologic oncology. 2006. PMID: 16962496
Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urologic oncology. 2006. PMID: 16962488
So-Rosillo R, Small EJ. Sipuleucel-T (APC8015) for prostate cancer. Expert review of anticancer therapy. 2006. PMID: 17020451
Kim H, Kim EK, Choi ES, Kim YJ, Lee HJ, Kim JJ, Jang HS, Shim KS, Jeon SN, Kang YH, Kang H, Oh J, Cho KS, Kwon S. [The determinants of adolescent smoking by gender and type of school in Korea]. Journal of preventive medicine and public health = Yebang Uihakhoe chi. 2006. PMID: 17076178